Spectroscopic Assessment of Tissue Oxygenation Changes in Plastic Surgical Flap Reconstructions

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorSpectrocor

About this trial

This study is a single-center, observational study designed to collect tissue spectrometric data.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults, age of 18 - 90 years

Scheduled for plastic surgical reconstructive flap operation

Ability and willingness to provide informed consent.

Disqualifiers

Unable to provide signed informed consent

Considered a vulnerable person according to the Finnish Medical Research Act (488/1999), Chapter 2, Sections 7, 9, and 10, including retarded persons, pregnant women, nursing mothers, prisoners, and forensic patients.

Trial population

Patients scheduled for plastic surgical reconstructive flap operation in the Helsinki University Central Hospital.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Observe changes in flap tissue oxygenation

To observe the changes in flap tissue oxygenation (combined hemoglobin/myoglobin saturation, %) measured by the SpectroCor Monitoring System during the ischemia-reperfusion sequence of microvascular flap reconstruction. Continuous spectroscopic measurement of combined hemoglobin and myoglobin oxygen saturation in the transferred flap tissue, recorded from a SpectroCor Sensor inserted into the flap, with a second sensor placed in subcutaneous tissue of the distal wound. Saturation values are time-stamped against intraoperative events affecting flap perfusion (pedicle division and flap detachment from the donor site, completion of the microvascular anastomosis, release of the vascular clamp and reperfusion, and any anastomotic revision) and compared with paired arterial and venous blood gas samples obtained at the beginning and at the end of the surgery.

Time frame
From sensor placement until sensor removal minutes before completion of surgery (intraoperative period, approximately 2-6 hours)

Secondary outcomes

1

Incidence of adverse events, adverse device effects, and device deficiencies

Number and proportion of participants experiencing at least one adverse event (AE), adverse device effect (ADE), serious adverse event (SAE), serious adverse device effect (SADE), or unanticipated serious adverse device effect (USADE), and the number of device deficiencies (DD) recorded. Events are recorded from the time of sensor placement until discharge from hospital and assessed for causal relationship to the investigational device by the investigator. Anticipated device-related events include topical bleeding at the sensor attachment site, local tissue reaction associated with tissue glue fixation, and local infection at the insertion site.

Time frame
From sensor placement during the operation until discharge from hospital (up to 30 days)

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Spectrocor

Lead sponsor

Helsinki University Central Hospital

Collaborator

This trial is not recruiting at the moment. You can still explore other options: